pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Journavx · news · pharmadog
← back to Journavx
News mentioning Journavx
18
stories
1d
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
3d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
10d
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
13d
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
13d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
16d
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
17d
STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
stat
17d
STAT+: Is there a pharma mega-merger in the making?
stat
17d
STAT+: BioNTech names Guido Oelkers its new CEO
stat
20d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
20d
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
endpoints
21d
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
stat
22d
NSF testing new Ph.D. model giving trainees academic and industry experience
stat
22d
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
Jul 20, 26
Pain drugmaker Latigo outlines plans to go public
biopharma dive
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 5, 26
Vertex earnings get muted investor response
biopharma dive
